Cencora to Buy American Oncology Network for $2.4B Enterprise Value; Lifts FY26 EPS View
COR sits 40% above its 52-week low of $244.82.
Summary
Cencora agreed to acquire American Oncology Network at a $2.4 billion enterprise value, paying roughly $1.7 billion in cash at closing to lift its stake to 75%, and raised the low end of its FY26 adjusted EPS outlook to at least $17.90.
Key Events · M&A and Partnerships · COR
-
Cencora to Acquire AON for $2.4B
A definitive merger agreement was signed October 20, 2026; Cencora will acquire all AON equity it does not already own, valuing AON at $2.4 billion enterprise value — $2.3 billion at closing plus up to $100 million in contingent value rights.
-
Cash Outlay of ~$1.7B at Closing
Cencora already holds about 4% of AON. Assuming AON holders roll over up to 25% of the equity, Cencora expects to pay roughly $1.7 billion at closing to reach 75% ownership.
-
FY26 Adjusted EPS Guidance Raised
Adjusted diluted EPS is now expected at least $17.90, the high end of the prior $17.75-$17.95 range, driven by strength in the U.S. Healthcare Solutions segment.
-
Accretion Expected in Year Two
Cencora expects the acquisition to be accretive to adjusted diluted EPS in the second year after closing.
Analysis · COR · Trade & Services
Cencora is buying the roughly 96% of American Oncology Network it does not already own, valuing AON at $2.4 billion enterprise value — $2.3 billion at closing plus up to $100 million in contingent value rights. Because some AON holders can roll up to 25% of their equity, Cencora expects to write a check of roughly $1.7 billion at closing to take its stake from about 4% to 75%. That is a meaningful but manageable outlay for a company of Cencora's size, and management expects the deal to add to adjusted EPS by the second year after closing. The same release nudges FY2026 adjusted EPS guidance to at least $17.90, the top of the prior $17.75-$17.95 range, on strength in U.S. Healthcare Solutions. The deal is not done: it needs regulatory clearances and an AON stockholder vote, and the FTC is already scrutinizing the separate Covetrus/MWI Animal Health transaction, so regulatory timing is the main open question. Cencora will lay out fiscal 2027 expectations on its November 4 earnings call.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 36.7% of the 1017 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.75%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, COR was trading at $342.51 on NYSE in the Trade & Services sector, with a market capitalization of approximately $65.5B. The 52-week trading range was $244.82 to $377.54. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.